359 related articles for article (PubMed ID: 36902015)
1. Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges.
Tian H; Zhang S; Liu Y; Wu Y; Zhang D
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902015
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast Growth Factor-Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications.
Jin L; Yang R; Geng L; Xu A
Annu Rev Pharmacol Toxicol; 2023 Jan; 63():359-382. PubMed ID: 36100222
[TBL] [Abstract][Full Text] [Related]
3. Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease.
Alisi A; Ceccarelli S; Panera N; Prono F; Petrini S; De Stefanis C; Pezzullo M; Tozzi A; Villani A; Bedogni G; Nobili V
PLoS One; 2013; 8(6):e67160. PubMed ID: 23840612
[TBL] [Abstract][Full Text] [Related]
4. The role of fibroblast growth factor 19 in the pathogenesis of nonalcoholic fatty liver disease.
Chrysavgis L; Giannakodimos I; Chatzigeorgiou A; Tziomalos K; Papatheodoridis G; Cholongitas E
Expert Rev Gastroenterol Hepatol; 2022 Sep; 16(9):835-849. PubMed ID: 36124827
[TBL] [Abstract][Full Text] [Related]
5. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.
Tillman EJ; Rolph T
Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast Growth Factor 19: Potential modulation of hepatic metabolism for the treatment of non-alcoholic fatty liver disease.
Sciarrillo CM; Keirns BH; Koemel NA; Anderson KL; Emerson SR
Liver Int; 2021 May; 41(5):894-904. PubMed ID: 33506572
[TBL] [Abstract][Full Text] [Related]
7. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.
Puengel T; Lefere S; Hundertmark J; Kohlhepp M; Penners C; Van de Velde F; Lapauw B; Hoorens A; Devisscher L; Geerts A; Boehm S; Zhao Q; Krupinski J; Charles ED; Zinker B; Tacke F
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743140
[TBL] [Abstract][Full Text] [Related]
8. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.
Liu J; Xu Y; Hu Y; Wang G
Metabolism; 2015 Mar; 64(3):380-90. PubMed ID: 25516477
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)?
Ritchie M; Hanouneh IA; Noureddin M; Rolph T; Alkhouri N
Expert Opin Investig Drugs; 2020 Feb; 29(2):197-204. PubMed ID: 31948295
[No Abstract] [Full Text] [Related]
10. Activating Adenosine Monophosphate-Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice.
Lin Q; Huang Z; Cai G; Fan X; Yan X; Liu Z; Zhao Z; Li J; Li J; Shi H; Kong M; Zheng MH; Conklin DJ; Epstein PN; Wintergerst KA; Mohammadi M; Cai L; Li X; Li Y; Tan Y
Hepatology; 2021 Jun; 73(6):2206-2222. PubMed ID: 32965675
[TBL] [Abstract][Full Text] [Related]
11. Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis.
Zarei M; Pizarro-Delgado J; Barroso E; Palomer X; Vázquez-Carrera M
Trends Pharmacol Sci; 2020 Mar; 41(3):199-208. PubMed ID: 31980251
[TBL] [Abstract][Full Text] [Related]
12. Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis.
Verzijl CRC; Van De Peppel IP; Struik D; Jonker JW
Expert Opin Investig Drugs; 2020 Feb; 29(2):125-133. PubMed ID: 31899984
[No Abstract] [Full Text] [Related]
13. Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes.
Barb D; Bril F; Kalavalapalli S; Cusi K
J Clin Endocrinol Metab; 2019 Aug; 104(8):3327-3336. PubMed ID: 30848827
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective.
Yadav P; Khurana A; Bhatti JS; Weiskirchen R; Navik U
Pharmacol Res; 2022 Oct; 184():106426. PubMed ID: 36075510
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease.
Su X; Kong Y; Peng D
Clin Chim Acta; 2019 Nov; 498():30-37. PubMed ID: 31419414
[TBL] [Abstract][Full Text] [Related]
16. Effective treatment of steatosis and steatohepatitis by fibroblast growth factor 1 in mouse models of nonalcoholic fatty liver disease.
Liu W; Struik D; Nies VJ; Jurdzinski A; Harkema L; de Bruin A; Verkade HJ; Downes M; Evans RM; van Zutphen T; Jonker JW
Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2288-93. PubMed ID: 26858440
[TBL] [Abstract][Full Text] [Related]
17. Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH).
Puengel T; Tacke F
Expert Opin Investig Drugs; 2023; 32(6):451-461. PubMed ID: 37376813
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease.
Raptis DD; Mantzoros CS; Polyzos SA
Ther Clin Risk Manag; 2023; 19():77-96. PubMed ID: 36713291
[TBL] [Abstract][Full Text] [Related]
19. The Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes.
Izaguirre M; Gil MJ; Monreal I; Montecucco F; Frühbeck G; Catalán V
Curr Diab Rep; 2017 Jun; 17(6):43. PubMed ID: 28451950
[TBL] [Abstract][Full Text] [Related]
20. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.
Hernandez GV; Smith VA; Melnyk M; Burd MA; Sprayberry KA; Edwards MS; Peterson DG; Bennet DC; Fanter RK; Columbus DA; Steibel JP; Glanz H; Immoos C; Rice MS; Santiago-Rodriguez TM; Blank J; VanderKelen JJ; Kitts CL; Piccolo BD; La Frano MR; Burrin DG; Maj M; Manjarin R
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G582-G609. PubMed ID: 32003601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
